Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. Sardesai has broad development and …

Top 4 Challenges for Vaccine Manufacturers

Recently we undertook the research for the 15th annual World Vaccine Congress, and so asked what the biggest challenges are for each segment of the market. When we spoke to vaccine manufacturers, these came up as the 4 biggest issues:   1)      Adjuvants Adjuvants are often lauded as the way forward to make vaccines more effective, but given how new …

Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets

May 27, 2014 Inovio Pharmaceuticals, Inc. today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license …

Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge

Protection Data Presented at the 17th Annual Meeting of the American Society of Gene & Cell Therapy May 27, 2014 Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV …

Inovio Pharmaceuticals Bolsters Research and Clinical Development Leadership

February 18, 2014 Inovio Pharmaceuticals, Inc. today announced it has expanded its senior management team with two appointments to help advance the company’s growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as Vice President of R&D and Dr. Jan Marie-Albert Van Tornout as Vice President of Clinical Development. Prior to Inovio, Dr. Humeau was Senior Director …

Interview: Analysing the potential for DNA vaccines

Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals was kind enough to take the time to speak to us to give his viewpoint on DNA Vaccines, in particular, their potential across a range of cancer indication. What is the potential for DNA vaccines across a broad range of cancer indications? It’s a great time to be in the DNA vaccine arena. There’s a …